Physician profile
Joseph Brewer
NPI 1811251283
$2,334.58
in general payments reported to CMS, 2019-2025
14 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $230 · 2021: $652 · 2023: $139 · 2024: $371 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $542.59 | 2020-2021 | |
| Abiomed | $400.92 | 2023-2025 | Impella |
| Abbott Laboratories | $388.76 | 2024-2025 | 2nd Gen Centrimag Primary Console, Freestyle Libre |
| Pfizer INC. | $229.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.36 | 2019-2020 | |
| Haemonetics Corporation | $111.30 | 2024 | Teg6s Hemostasis System |
| United Therapeutics Corporation | $108.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $97.86 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $97.14 | 2019 | |
| Mallinckrodt Enterprises LLC | $81.92 | 2019 | |
| Astellas Pharma US INC | $57.82 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $52.49 | 2021 | |
| La Jolla Pharmaceutical Company | $29.04 | 2020-2025 | Giapreza |
| Chiesi USA, INC. | $21.65 | 2024 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.